Greg Cima

The Ireland-based firm said its inexpensive capacitance-based assays deliver "molecular detection by proxy," providing rapid, multiplex, quantitative results.

In a bid to expand recognition and treatment of alpha-1 antitrypsin deficiency, a cause of COPD, Grifols is making its over-the-counter genetic test available for free.

Lucira Health won't be the last COVID-19-focused firm to face bankruptcy, layoffs, or stock price declines, as "COVID cash" dries up, experts said.

The firm's earnings slid as COVID-19 testing revenues plummeted to $31 million in Q4 2022 from $336 million a year ago.

A decline in demand for rapid COVID-19 antigen tests dragged on the company's diagnostics division while lockdowns in China reduced routine testing.

The firm beat predictions for the quarter on the strength of its other molecular diagnostics business, and it predicts double-digit revenue growth for the year. 

The firm is developing a shoebox-size gas chromatography instrument that could be used for routine screenings and critical illness detection and monitoring.

The Cue Health-sponsored ImmunoCare study is testing the value of giving immunocompromised people at-home tests, telemedicine, and prescription delivery.

At the JP Morgan Healthcare conference, CEO Steve MacMillan especially noted Africa as an underserved market for women's health.

The lightweight, portable instruments coming onto the market employ promise to deliver test results closer to patients, potentially hastening treatments.